PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
1280.26%
Cash & equivalents yoy growth at least 1.5x RVPH's 95.93%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Cash + STI yoy ≥ 1.5x RVPH's 95.93%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
≥ 1.5x RVPH's 72.84%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
≥ 1.5x RVPH's 64.40%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Exceeding 1.5x RVPH's 8.21%. Michael Burry suspects ballooning short-term obligations vs. competitor.
92.39%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
50.95%
Higher Long-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.95%
Less than half of RVPH's -40.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
54.32%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.21%
Similar yoy to RVPH's -3.55%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.60%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
1280.26%
≥ 1.5x RVPH's 64.40%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
50.95%
Less than half of RVPH's -49.51%. David Dodd sees less overall debt expansion vs. competitor.
22.84%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.